ZyVersa secures European patent for VAR 200 to treat inflammatory and renal diseases
ZyVersa’s Cholesterol Efflux Mediator VAR 200 is currently in Phase 2a development to reduce renal cholesterol and lipid…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
10 Jul 23
ZyVersa’s Cholesterol Efflux Mediator VAR 200 is currently in Phase 2a development to reduce renal cholesterol and lipid…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
10 Jul 23
By selecting ABEC, Lilly aims to capitalise on ABEC's CSR technology for the upstream and downstream processes of…
07 Jul 23
Leqembi is a humanised immunoglobulin gamma 1 (IgG1) monoclonal antibody therapy, initially approved to treat AD in adults,…
07 Jul 23
As per the terms of the agreement, F-star and Takeda will jointly conduct research and development activities focused…
06 Jul 23
Biocon Biologics has transitioned a portfolio of biosimilars including bTrastuzumab, bPegfilgrastim, bBevacizumab, bGlargine, bAspart, bAdalimumab, and bEtanercept, which…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
06 Jul 23
Under the MOU, both firms will improve Thailand’s capacity for vaccine development and production and will also work…
06 Jul 23
Under the contract, Evotec Biologics will develop drug product prototype(s) from discovery through the execution of Phase 1…
06 Jul 23
Brii Biosciences has acquired worldwide exclusive license to VBI-2601 and an exclusive license for PreHevbri in the Asia…
05 Jul 23
The EC authorisation is supported by positive data from the Phase ½ FOENIX-CCA2 clinical trial, in which Lytgobi…
04 Jul 23
The first Phase 3 results for AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody drug conjugate showed a statistically significant…